CASE DISCUSSION
H. pylori Treatment with PYELRA®: Best Practices
Presented from India by Dr. Filippos Georgopoulos0
Likes
606591
Views
24,264
Shares
30,330
Bookmarks
0
Credit Points
0
Learning Hours
0
CPD/CME Points
0
Courses Completed
Case Description
PYLERA® is a medication used for the treatment of Helicobacter pylori (H. pylori) infection, a common cause of stomach ulcers and gastritis. It contains a combination of three active ingredients: bismuth subcitrate potassium, metronidazole, and tetracycline. This combination works synergistically...
Case Summary
- Helicobacter pylori is a common chronic bacterial infection affecting 50-60% of the global population, with varying prevalence across regions and socioeconomic conditions. Transmission occurs via fecal-oral or gastric-oral routes, often during childhood, leading to chronic gastritis. While most infected individuals remain asymptomatic, H. pylori can contribute to peptic ulcer disease, gastric cancer, ITP, and iron/B12 deficiency anemia.
Speaker Profile
Dr. Filippos Georgopoulos
Head of the Gastroenterology Department and Endoscopy, Al Zahra Private Hospital, DubaiDr. Filippos Georgopoulos is currently working as Consultant in Gastroenterology and Hepatology and heads the Gastroenterology Department and Endoscopy Unit at Al Zahra Private Hospital in Dubai. He is a Fellow of the European Board of Gastroenterology and Hepatology (FEBGH), UAE.
Disclosures
Assimilate requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships for anyone with the ability to control the content of this educational activity have been reviewed and mitigated. Others involved in the planning of this activity have no relevant financial relationships.